Domzalski David has filed 16 insider transactions across 1 company since January 2024.
Most recent transaction: a tax payment of 14232 shares of VYNE Therapeutics Inc. ($VYNE) on March 31, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | VYNE Therapeutics Inc. | $VYNE | Domzalski David | PRESIDENT AND CEO | F | Common Stock | 14232 | $0.60 | 401,976.0000 | 42,589,000 | 3.42% | 0.03% |
| Dec. 31, 2025 | VYNE Therapeutics Inc. | $VYNE | Domzalski David | PRESIDENT AND CEO | F | Common Stock | 12684 | $0.58 | 416,208.0000 | 42,589,000 | 2.96% | 0.03% |
| Sept. 30, 2025 | VYNE Therapeutics Inc. | $VYNE | Domzalski David | PRESIDENT AND CEO | F | Common Stock | 12676 | $0.34 | 428,892.0000 | 42,589,000 | 2.87% | 0.03% |
| June 30, 2025 | VYNE Therapeutics Inc. | $VYNE | Domzalski David | PRESIDENT AND CEO | F | Common Stock | 12676 | $1.65 | 441,568.0000 | 42,589,000 | 2.79% | 0.03% |
| June 2, 2025 | VYNE Therapeutics Inc. | $VYNE | Domzalski David | PRESIDENT AND CEO | A | Common Stock | 8681 | $0.81 | 454,244.0000 | 42,589,000 | 1.95% | 0.02% |
| March 31, 2025 | VYNE Therapeutics Inc. | $VYNE | Domzalski David | PRESIDENT AND CEO | F | Common Stock | 30498 | $1.58 | 445,563.0000 | 42,589,000 | 6.41% | 0.07% |
| Jan. 21, 2025 | VYNE Therapeutics Inc. | $VYNE | Domzalski David | PRESIDENT AND CEO | A | Stock Option (right to buy) | 730000 | $0.00 | 730,000.0000 | 42,589,000 | 9999.99% | 1.71% |
| Dec. 31, 2024 | VYNE Therapeutics Inc. | $VYNE | Domzalski David | PRESIDENT AND CEO | F | Common Stock | 24536 | $3.35 | 476,061.0000 | 10,273,000 | 4.90% | 0.24% |
| Nov. 30, 2024 | VYNE Therapeutics Inc. | $VYNE | Domzalski David | PRESIDENT AND CEO | A | Common Stock | 3901 | $2.10 | 500,597.0000 | 10,273,000 | 0.79% | 0.04% |
| Sept. 30, 2024 | VYNE Therapeutics Inc. | $VYNE | Domzalski David | PRESIDENT AND CEO | F | Common Stock | 685 | $1.88 | 496,696.0000 | 10,273,000 | 0.14% | 0.01% |
| July 1, 2024 | VYNE Therapeutics Inc. | $VYNE | Domzalski David | PRESIDENT AND CEO | F | Common Stock | 935 | $1.92 | 497,654.0000 | 10,273,000 | 0.19% | 0.01% |
| May 31, 2024 | VYNE Therapeutics Inc. | $VYNE | Domzalski David | PRESIDENT AND CEO | A | Common Stock | 4429 | $2.16 | 498,589.0000 | 10,273,000 | 0.90% | 0.04% |
| April 1, 2024 | VYNE Therapeutics Inc. | $VYNE | Domzalski David | PRESIDENT AND CEO | F | Common Stock | 1004 | $3.08 | 494,160.0000 | 10,273,000 | 0.20% | 0.01% |
| Jan. 1, 2024 | VYNE Therapeutics Inc. | $VYNE | Domzalski David | President and CEO | A | Stock Option (right to buy) | 225000 | $0.00 | 225,000.0000 | 10,273,000 | 9999.99% | 2.19% |
| Jan. 2, 2024 | VYNE Therapeutics Inc. | $VYNE | Domzalski David | President and CEO | F | Common Stock | 1004 | $2.28 | 495,164.0000 | 10,273,000 | 0.20% | 0.01% |
| Jan. 1, 2024 | VYNE Therapeutics Inc. | $VYNE | Domzalski David | President and CEO | A | Common Stock | 225000 | $0.00 | 496,168.0000 | 10,273,000 | 82.97% | 2.19% |